Royal Bank of Canada initiated coverage on Outset Medical in a report on Friday, November 11th. Cowen dropped their price objective on Outset Medical to $22.00 in a report on Tuesday, November 15th. OM has been the topic of several research reports. Company insiders own 4.00% of the company’s stock. Insiders sold a total of 147,263 shares of company stock worth $3,650,017 over the last 90 days. The disclosure for this sale can be found here. Following the transaction, the general counsel now owns 66,422 shares of the company’s stock, valued at $1,618,039.92. The stock was sold at an average price of $24.36, for a total value of $33,080.88. Brottem sold 1,358 shares of Outset Medical stock in a transaction that occurred on Thursday, February 16th. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Following the completion of the sale, the chief executive officer now directly owns 414,044 shares in the company, valued at approximately $11,618,074.64. The shares were sold at an average price of $28.06, for a total transaction of $841,800.00. In other news, CEO Leslie Trigg sold 30,000 shares of Outset Medical stock in a transaction that occurred on Wednesday, February 1st. Following the completion of the sale, the general counsel now directly owns 66,422 shares in the company, valued at approximately $1,618,039.92. The shares were sold at an average price of $24.36, for a total transaction of $33,080.88. will post -3.6 earnings per share for the current year. On average, equities research analysts expect that Outset Medical, Inc. During the same quarter last year, the company posted ($0.87) earnings per share. Outset Medical had a negative return on equity of 55.22% and a negative net margin of 141.24%. The firm had revenue of $32.01 million for the quarter, compared to analyst estimates of $31.51 million. The company reported ($0.86) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.02. Outset Medical ( NASDAQ:OM – Get Rating) last released its quarterly earnings results on Monday, February 13th. Hedge funds and other institutional investors own 98.84% of the company’s stock. Quantbot Technologies LP now owns 9,779 shares of the company’s stock valued at $145,000 after buying an additional 3,197 shares during the last quarter. Finally, Quantbot Technologies LP increased its holdings in Outset Medical by 48.6% in the second quarter. US Bancorp DE now owns 4,068 shares of the company’s stock valued at $65,000 after buying an additional 1,471 shares during the last quarter. US Bancorp DE increased its holdings in Outset Medical by 56.6% in the third quarter. Nisa Investment Advisors LLC now owns 2,060 shares of the company’s stock valued at $31,000 after buying an additional 1,200 shares during the last quarter. Nisa Investment Advisors LLC increased its holdings in Outset Medical by 139.5% in the second quarter. Point72 Hong Kong Ltd purchased a new position in Outset Medical in the second quarter valued at $27,000. now owns 1,812 shares of the company’s stock valued at $27,000 after buying an additional 1,440 shares during the last quarter. increased its holdings in Outset Medical by 387.1% in the second quarter. Several other large investors have also recently bought and sold shares of OM. Barclays PLC’s holdings in Outset Medical were worth $32,000 at the end of the most recent reporting period. The institutional investor owned 2,033 shares of the company’s stock after selling 599,372 shares during the period. ( NASDAQ:OM – Get Rating) by 99.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. Barclays PLC reduced its stake in Outset Medical, Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |